Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in BRCA2 and taxane resistance in prostate cancer.

Scientific reports - 4 Jul 2017

Nientiedt Cathleen, Heller Martina, Endris Volker, Volckmar Anna-Lena, Zschäbitz Stefanie, Tapia-Laliena María A, Duensing Anette, Jäger Dirk, Schirmacher Peter, Sültmann Holger, Stenzinger Albrecht, Hohenfellner Markus, Grüllich Carsten, Duensing Stefan

Abstract excerpt

Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged-Ring Compounds
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation Rate

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 28676659
DOI: 10.1038/s41598-017-04897-x
PMCID: PMC5496866

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Mutations in BRCA2 and taxane resistance in prostate cancer.PMID 28676659Read ↗

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Semantic proximity Read ↗

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.Semantic proximity Read ↗

Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatmentsSemantic proximity Read ↗

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.Semantic proximity Read ↗

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based ChemotherapySemantic proximity Read ↗

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.Semantic proximity Read ↗

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Semantic proximity Read ↗

Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant BRCA2 mutation positive prostate cancer patientSemantic proximity Read ↗

Rapid progression of prostate cancer in men with a BRCA2 mutation.Semantic proximity Read ↗

Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.